tirzepatide phase 3 mash New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024 Eli Lilly's tirzepatide shows promise

This dual effect means that maintaining muscle mass is a key concern for menopausal women using GLP-1 medications

Once-Weekly Semaglutide in Adults With Overweight or Obesity (STEP-1 Trial, 2021) showed significant weight loss and metabolic improvements with weekly semaglutide + lifestyle intervention versus placebo

Overweight and obesity are as much of a problem for people with type 1 diabetes as for those without the condition

A midweek injection means you can adjust by a day or two in either direction without violating the 72-hour rule, giving you room to accommodate shifting travel schedules

K., Cunningham, C., Webb, T